Chai Discovery Raises $400 Million Series C To Advance AI-Driven Molecular Design
Article excerpt
Highlighted: the sentence this signal was extracted from
Chai Discovery announced a $400 million Series C financing to accelerate the development and deployment of its AI-driven molecular design platform. The round valued Chai Discovery at $3.8 billion. It was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension. New investors in the round included Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, and other notable investors. Existing investors Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite also participated. Chai Discovery builds AI models designed to accelerate pre-clinical drug discovery by predicting and reprogramming interactions between molecules. The company's software platform gives scientists at pharmaceutical and life sciences companies access to those models, helping them design better molecules and pursue difficult targets. The company said its platform is already being used by leading pharmaceutical companies, including Eli Lilly and Pfizer. Chai Discovery's broader mission is to bring the precision and predictability of engineering to drug discovery, including for "hard-to-drug" and "undruggable" targets that traditional discovery methods have struggled to address. The financing comes as AI drug discovery moves from early promise into commercial deployment. Chai Discovery...
Keep reading with a free account
The rest of this article, and every signal for Chai Discovery, is in your free account.
